Drug Trial Radar · NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
626
Planned (sponsor's estimate)
Start
Dec 2, 2020
Primary completion
Oct 31, 2028
Study completion Oct 31, 2029
Sponsor
- Lead sponsor
- Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.
Conditions
- Advanced Non-Small Cell Lung Cancer
- Metastatic Non-Small Cell Lung Cancer
Interventions
AdagrasibDrug
Adagrasib 400 mg twice daily (BID) in combination with pembrolizumab (Cohort 1a)
AdagrasibDrug
Adagrasib 600 mg BID monotherapy (Cohort 1b)
AdagrasibDrug
adagrasib 400 mg BID in combination with pembrolizumab
AdagrasibDrug
Adagrasib 400 mg BID + pembrolizumab 200 mg every Q3W
PembrolizumabDrug
Pembrolizumab 200 mg IV Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: To evaluate the efficacy of Adagrasib monotherapy and in combination with pembrolizumab administered to patients having advanced/metastatic NSCLC.Time frame: 22 months
- Phase 3: To compare efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumabTime frame: 36 months
Locations
776 sites in 47 countries. Site status is shown where the registry gives one.
Local Institution - 007-556-A
Goodyear, Arizona · Not yet recruiting
USOR - Arizona Oncology - Prescott Valley
Prescott Valley, Arizona · Recruiting
Local Institution - 007-568-A
Safford, Arizona · Not yet recruiting
Local Institution - 007-568-B
Safford, Arizona · Not yet recruiting
Local Institution - 007-568-C
Safford, Arizona · Not yet recruiting
Local Institution - 007-568-D
Safford, Arizona · Not yet recruiting
Local Institution - 007-568-E
Safford, Arizona · Not yet recruiting
Arizona Clinical Research Center
Tucson, Arizona · Recruiting
Highlands Oncology Group - Springdale
Springdale, Arkansas · Recruiting
Providence - Saint Joseph Home Health - Anaheim
Anaheim, California · Recruiting
The Oncology Institute of Hope and Innovation - Corporate Office
Cerritos, California · Recruiting
Local Institution - 007-777
Fountain Valley, California · Not yet recruiting
Local Institution - 007-778
Laguna Hills, California · Not yet recruiting
Local Institution - 007-898-B
Long Beach, California · Not yet recruiting
MemorialCare - Long Beach Medical Center
Long Beach, California · Recruiting
TRIO - Cancer & Blood Specialty Clinic - Los Alamitos
Los Alamitos, California · Recruiting
Local Institution - 007-579
Los Angeles, California · Withdrawn
Local Institution - Unk045
Rancho Mirage, California · Active not recruiting
San Francisco Veterans Affairs Medical Center
San Francisco, California · Recruiting
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California · Recruiting
Local Institution - 007-898-C
Santa Ana, California · Not yet recruiting
Providence Medical Group - Santa Rosa
Santa Rosa, California · Recruiting
Stockton Hematology Oncology Medical Group (SHOMG) - Stockton (Suite B)
Stockton, California · Recruiting
Local Institution - 007-898-A
Whittier, California · Not yet recruiting
Local Institution - 007-872-H
Aurora, Colorado · Not yet recruiting
Local Institution - 007-872-D
Boulder, Colorado · Not yet recruiting
Local Institution - 007-872-L
Centennial, Colorado · Not yet recruiting
Local Institution - 007-872-C
Colorado Springs, Colorado · Not yet recruiting
Local Institution - 007-872-K
Colorado Springs, Colorado · Not yet recruiting
Local Institution - 007-872-E
Denver, Colorado · Not yet recruiting
Local Institution - 007-872-I
Denver, Colorado · Not yet recruiting
Local Institution - 007-872-A
Lakewood, Colorado · Not yet recruiting
Local Institution - 007-872-J
Littleton, Colorado · Not yet recruiting
USOR - Rocky Mountain Cancer Centers - Lone Tree
Lone Tree, Colorado · Recruiting
Local Institution - 007-872-G
Longmont, Colorado · Not yet recruiting
Local Institution - 007-872-B
Pueblo, Colorado · Not yet recruiting
Local Institution - 007-872-F
Thornton, Colorado · Not yet recruiting
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut · Recruiting
Local Institution - 007-5476
Washington D.C., District of Columbia · Not yet recruiting
GenesisCare USA
Aventura, Florida · Recruiting
Showing 40 of 776 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.